CLL Coverage from Every Angle

Barbara Eichhorst, MD, on Clinical Implications of New Findings on Venetoclax, Obinutuzumab, and Chemoimmunotherapy for CLL

Posted: Monday, October 3, 2022

Barbara Eichhorst, MD, of the German CLL Study Group and the University of Cologne, offers some clinical pearls on results from the GAIA/CLL13 trial, which showed that venetoclax, obinutzumab, and ibrutinib or venetoclax plus obinutzumab improved progression-free survival compared with standard chemoimmunotherapy in fit, previously untreated patients with chronic lymphocytic leukemia.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.